Furthermore, soluble ST2 monitoring has demon strated to be potentially useful also in therapeu tic decision making in these patients. 5 Thus, all these biomarkers have emerged as being poten tially useful for the practicing clinician.
A number of studies have shown that neutro phils are independent predictors of a poor clin ical outcome in various cardiac diseases, includ ing stable coronary artery disease as well as acute coronary syndromes. 6 Moreover, neutrophil tolymphocyte ratio (NLR) has been found to be a negative predictor of allcause mortality in patients undergoing coronary angiography or in vasive revascularization. 7 Neutrophils probably act directly to determine myocardial tissue dam age besides being part of the acute inflammatory response to tissue injury. 7 In patients with acute coronary syndromes, neutrophils are functional ly activated and local neutrophil infiltration has been documented in culprit plaque lesions sug gesting the role of neutrophils in destabilization of atherosclerotic plaques. 8 Furthermore, acti vated polymorphonuclear leukocytederived mic roparticles may enhance coagulation and promote thrombus formation thanks to platelet activation and their expression of Pselectin. Thus, the NLR may be considered a new systemic inflammatory marker and has been proposed as a risk stratifica tion index in order to predict longterm mortality in patients with several cardiovascular diseases.
A number of studies have suggested an involve ment of the immune system also in the patho genesis and progression of HF.
8 A lowgrade in flammatory response, as a result of various stim uli (ischemia, infection, toxins, neurohormonal activation), appears to be necessary to start the repair of the injured heart, but it may also con tribute to death of cardiac myocytes, hypertro phy, fibrosis, and loss of the normal cardiac struc ture. In the acute phase, progression to HF can be due to a consistent loss of myocytes, and in the Heart failure (HF) is a multifactorial disease de termined by inability of the heart to deliver oxy gen to tissues to meet body's metabolic require ments. 1 HF is extremely common and progres sively increases with age; its incidence reaches from 5 to 10 persons per 1000 per year for an es timated prevalence of 1% to 2% of the adult pop ulation in the Western world.
2 Unfortunately, de spite the progress in the treatment of this dis ease, its prognosis is still poor with a 40% risk of death or readmission to the hospital at 1 year.
1,3
Thus, adequate risk stratification appears to be of paramount importance for the management of HF patients. Typically, several clinical charac teristics such as age, sex, New York Heart Asso ciation classification, cause of HF, and the pres ence of relevant comorbidities have been evalu ated to assess the prognosis of patients with HF. Furthermore, an echocardiographic assessment of ventricular function indices (ejection fraction, ventricular mass) is considered essential for their risk stratification.
The evaluation of a number of laboratory bio markers has been proposed to complement the prognostic assessment of HF patients. Btype na triuretic peptide and its inactive form, Ntermi nal proBtype natriuretic peptide, are widely used in diagnostic workup of patients with suspicion of acutely decompensated HF. Beyond their val ue for diagnostic evaluation, natriuretic peptides have been shown in numerous studies to be use ful also in stratifying the risk for rehospitaliza tion and death of these patients. 4 Highly sensi tive troponin provides important prognostic in formation in the context of acute decompensated HF and seems to play an integral role in the eval uation of HF patients. Concentrations of soluble ST2, a protein found to be upregulated in the case of mechanical strain in cardiac myocytes, have been associated both with HF symptom severity and with risk of short and longterm mortality. chronic phase, it may be due to a lowlevel apop tosis. Cell death is localized both in the affected ischemic zone and also in the more remote myo cardium, which consequently leads to a reduction in contractile reserve and to progression of HF.
A few studies have assessed the prognostic role of the NLR in patients with HF. 9,10 In the cur rent issue of Polish Archives of Internal Medicine (Pol Arch Med Wewn), Wasilewski et al, 11 using data of the COMMITHF registry, reported im portant findings on the role of the NLR in pre dicting long term mortality in patients with HF of different etiologies. In this large cohort (1734 patients), a high NLR was significantly associat ed with an increased risk of 12month allcause mortality in the subpopulation of patients with an ischemic etiology of HF, but not in patients with a nonischemic HF. As underlined by the au thors, the NLR is an inexpensive and may gen erally be measured in all HF patients admitted to the hospital. In addition, considering the fre quency of ischemic origin of HF and the progno sis of these patients, the evaluation of the NLR may be particularly useful for clinicians.
If the results of Wasilewski et al 11 are confirmed in other large prospective studies, the NLR may be evaluated along with other prognostic mark ers in all patients presenting with HF of ischemic origin to improve the risk stratification of these patients. Furthermore, the results open the way to other studies that may evaluate new therapeu tic approaches in these patients. Statins and tu mor necrosis factorα inhibitors have been pro posed to modify the inflammatory status of pa tients with several cardiovascular and noncardio vascular diseases.
12 Assessment of the NLR in pa tients with HF may help identify the subgroup of patients who may derive more benefit from treat ment with these drugs. However, we have to wait for the results of highquality randomized con trolled trials in this setting before implementing these findings to clinical practice.
